Cargando…
Cyclosporin-A reduced the cytotoxicity of propranolol in HUVECs via p38 MAPK signaling
Propranolol (PROP) is a nonselective β-adrenergic receptor antagonist used to treat hypertension and cardiac arrhythmias. Oral administration of PROP has recently emerged as a new treatment modality for hemangiomas. However, the side effects of PROP at the cellular level have not been adequately des...
Autores principales: | Lv, Zhong, Xie, Guanhao, Cui, Haowen, Yao, Zhi, Shao, Congxiang, Yuan, Weiquan, Chen, Bailing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797567/ https://www.ncbi.nlm.nih.gov/pubmed/35089188 http://dx.doi.org/10.1097/MD.0000000000028329 |
Ejemplares similares
-
The impact of propranolol on the growth and development of children with proliferative infantile hemangioma during treatment
por: Lin, Xiangshang, et al.
Publicado: (2023) -
Combined effect of propranolol, vincristine and bevacizumab on HUVECs and BJ cells
por: Bota, Mădălina, et al.
Publicado: (2019) -
Infantile hepatic hemangioendothelioma associated with pulmonary artery hypertension and cardiac insufficiency successfully treated with transcatheter arterial embolization and propranolol: A case report
por: Wang, Liang, et al.
Publicado: (2020) -
Propranolol Suppresses Proliferation and Migration of HUVECs through Regulation of the miR-206/VEGFA Axis
por: Zhang, Ting, et al.
Publicado: (2021) -
A pan-cancer analysis of the MAPK family gene and their association with prognosis, tumor microenvironment, and therapeutic targets
por: Qin, Yuan-Yuan, et al.
Publicado: (2023)